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Does Elevated C-Reactive Protein
Increase Atrial Fibrillation Risk?
A Mendelian Randomization of 47,000 Individuals
From the General Population
Sarah C. W. Marott, MD,*†‡ Børge G. Nordestgaard, MD, DMSC,*†‡§
Jeppe Zacho, MD,*†‡ Jens Friberg, MD, PHD,‡ Gorm B. Jensen, MD, DMSC,‡§
Anne Tybjærg-Hansen, MD, DMSC,†‡§¶ Marianne Benn, MD, PHD*†‡§
Herlev and Copenhagen, Denmark
Objectives The purpose of this study was to test whether the association of C-reactive protein (CRP) with increased risk of
atrial fibrillation is a robust and perhaps even causal association.
Background Elevated levels of CRP previously have been associated with increased risk of atrial fibrillation.
Methods We studied 10,276 individuals from the prospective Copenhagen City Heart Study, including 771 individuals who
had atrial fibrillation during follow-up, and another 36,600 persons from the cross-sectional Copenhagen Gen-
eral Population Study, including 1,340 cases with atrial fibrillation. Individuals were genotyped for 4 CRP gene
polymorphisms and had high-sensitivity CRP levels measured.
Results A CRP level in the upper versus lower quintile associated with a 2.19-fold (95% confidence interval [CI]: 1.54- to
3.10-fold) increased risk of atrial fibrillation. Risk estimates attenuated slightly after multifactorial adjustment to
1.77 (95% CI: 1.22 to 2.55), and after additional adjustment for heart failure and plasma fibrinogen level to
1.47 (95% CI: 1.02 to 2.13) and 1.63 (95% CI: 1.21 to 2.20), respectively. Genotype combinations of the 4 CRP
polymorphisms associated with up to a 63% increase in plasma CRP levels (p  0.001), but not with increased
risk of atrial fibrillation. The estimated causal odds ratio for atrial fibrillation by instrumental variable analysis for
a doubling in genetically elevated CRP levels was lower than the odds ratio for atrial fibrillation observed for a
doubling in plasma CRP on logistic regression (0.94 [95% CI: 0.70 to 1.27] vs. 1.36 [95% CI: 1.30 to 1.44];
p  0.001).
Conclusions Elevated plasma CRP robustly associated with increased risk of atrial fibrillation; however, genetically elevated
CRP levels did not. This suggests that elevated plasma CRP per se does not increase atrial fibrillation risk.
(J Am Coll Cardiol 2010;56:789–95) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.066fi
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alevated levels of C-reactive protein (CRP) have been
uggested as a possible contributing factor to the initiation
r maintenance of atrial fibrillation. However, whether
ncreased plasma CRP levels are simply a marker for atrial
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010, accepted February 25, 2010.brillation or whether elevated CRP actually contributes
irectly to causing the disorder presently is unknown (1,2).
his question has clinical importance because several car-
iovascular drugs, such as angiotensin-converting enzyme
nhibitors and angiotensin receptor blockers, modulate the
nflammatory process in the heart (3,4), and because drugs
hat specifically lower CRP levels already are being devel-
ped for treatment of cardiovascular disease (5).
Cause-and-effect relationships such as the one suggested
etween plasma CRP levels and risk of atrial fibrillation can
e studied using an approach called Mendelian randomiza-
ion (6). This approach uses genetic variants randomly
ssorted during gamete formation and associated with levels
f plasma CRP to test whether there could be a causal
ssociation between elevated plasma CRP levels and in-
reased risk of atrial fibrillation. Thus, genetic variants that
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of CRP (7) can be used as instru-
ments to assess the consequences
of lifelong high CRP levels inde-
pendently of other risk factors
and not hampered by reverse
causation (8).
We tested the hypothesis that
there is a robust and potential
ausal association between elevated CRP levels and in-
reased risk of atrial fibrillation. Robustness was tested by
djustment of risk estimates for age, sex, and statin use; age,
ex, statin use, and CRP genotype; multifactorially for age,
ex, statin use, low-density lipoprotein (LDL) cholesterol,
ody mass index, smoking, heavy drinking, diabetes melli-
us, hypertension, and hyperthyroidism; multifactorially in-
luding heart failure, AGT-20A¡C, AGT T174M, and
CE insertion or deletion genotypes; or finally, including
haracteristics of Individuals in the 2 General Population Studies bTable 1 Characteristics of Individuals in the 2 General Populat
1 2
Copenhagen City Heart Study
CRP (mg/dl) 1.0 (0.1–1.2) 1.3 (1.2–1.
No. of individuals 1,656 1,657
Women 47 56
Age (yrs) 50 (37–63) 57 (44–68
Statin use 0.5 0.8
LDL cholesterol (mmol/l) 3.3 (2.7–4.1) 3.6 (2.9–4.
Body mass index (kg/m2) 23 (21–25) 24 (22–27
Smoking, active and former 51 56
Heavy drinkers 10 10
Diabetes mellitus 2 3
Hypertension 38 48
Hyperthyroidism 2 2
Heart failure 4 7
Fibrinogen (mg/l) 2.5 (2.1–2.9) 2.7 (2.3–3.
AGT-29 A¡C (AA/AC/CC) 70/27/3 70/27/3
AGT T174M (TT/TM/MM) 77/22/2 76/23/2
ACE ins/del (dd/id/ii) 26/50/24 26/49/24
Copenhagen General Population Study
CRP (mg/dl) 0.5 (0.01–0.8) 1.1 (0.8–1.
No. of individuals 7,331 7,320
Women 53 52
Age (yrs) 53 (45–63) 58 (48–66
Statin use 6 10
LDL cholesterol (mmol/l) 3.1 (2.2–3.7) 3.1 (2.5–3.
Body mass index (kg/m2) 24 (24–26) 25 (23–27
Smoking, active and former 55 45
Heavy drinkers 2 3
Diabetes mellitus 2 3
Hypertension 55 63
Hyperthyroidism 1 1
Heart failure 1 1
Fibrinogen (mg/l) 1.0 (0.9–1.2) 1.1 (1.0–1.
ontinuous values are summarized as median (interquartile range); p value is for trend among quin
Abbreviations
and Acronyms
CI  confidence interval
CRP  C-reactive protein
OR  odds ratio
LDL  low-density
lipoproteiny Cuzick’s extension of a Wilcoxon rank-sum test.
CRP  C-reactive protein; LDL  low-density lipoprotein.lasma fibrinogen. Potential causality was tested by exam-
ning whether CRP genotype combinations associated with
n increased risk of atrial fibrillation consistent with their
ife-long elevation of plasma CRP levels.
ethods
or full information on study populations, genotyping and
iochemical analyses, covariates, and statistical analyses, please
efer to Supplementary Methods. The CCHS (Copenhagen
ity Heart Study) is a prospective study of the Danish general
opulation initiated from 1976 through 1978 with follow-up
xaminations in 1981 through 1983, 1991 through 1994, and
001 through 2003 (9). The CGPS (Copenhagen General
opulation Study) is a cross-sectional study initiated in 2003
ith ongoing inclusion. Participants were ascertained exactly as
n the CCHS. All participants were white and of Danish
sma CRP Quintilestudies by Plasma CRP Quintiles
uintiles of Plasma CRP
p Value3 4 5
1.7 (1.5–2.1) 2.7 (2.1–3.6) 9.9 (3.6–103) 0.001
1,654 1,654 1,655
58 55 56 0.001
61 (50–70) 64 (53–72) 64 (55–72) 0.001
0.9 1.2 0.2 0.001
3.8 (3.1–4.5) 3.8 (3.1–4.7) 3.7 (3.0–4.5) 0.001
25 (23–28) 26 (24–29) 27 (24–30) 0.001
60 66 69 0.001
10 9 10 0.52
3 5 8 0.001
57 65 65 0.001
2 2 3 0.06
10 15 19 0.001
2.9 (2.5–3.4) 3.2 (2.8–3.7) 3.8 (3.2–4.5) 0.001
72/26/2 72/25/3 70/28/2 0.71
79/19/1 77/21/2 77/21/1 0.29
26/50/24 26/48/25 25/51/24 0.56
1.5 (1.3–1.9) 2.5 (1.9–3.4) 8.7 (3.4–330) 0.001
7,316 7,315 7,318
53 52 57 0.001
59 (49–67) 60 (50–69) 62 (51–71) 0.001
11 11 11 0.001
3.2 (2.6–3.9) 3.3 (2.7–4.0) 3.3 (2.6–3.9) 0.001
26 (23–28) 27 (24–30) 28 (25–31) 0.001
39 49 58 0.12
3 3 3 0.02
3 4 6 0.001
67 72 77 0.001
1 1 2 0.02
1 2 4 0.001
1.2 (1.0–1.3) 1.3 (1.1–1.4) 1.4 (1.2–1.7) 0.001
a nonparametric test by Cuzick. Categorical values are summarized in percent; p values for trendy Plaion S
Q
5)
)
3)
)
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3)
)
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)
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August 31, 2010:789–95 Elevated CRP and Atrial Fibrillationescent. No individuals were included in both populations, and
ollow-up was 100% complete.
esults
haracteristics of participants in each study cohort are
hown in Table 1 as a function of quintiles of plasma CRP.
n each cohort, increasing plasma CRP levels associated
ith female sex, increasing age, plasma LDL cholesterol,
ody mass index, and fibrinogen levels and with presence of
tatin use, smoking, diabetes mellitus, hypertension, and
eart failure (all p  0.001 for trend) (Table 1). Levels of
lasma CRP did not associate with distribution of AGT or
CE genotype (Table 1).
lasma CRP and risk of atrial fibrillation. Increasing
evels of plasma CRP were associated with increasing risk of
trial fibrillation (Fig. 1). In the CCHS population, CRP in
he upper versus lower quintile was associated with a
.19-fold (95% confidence interval [CI]: 1.54- to 3.10-fold)
ncreased risk of atrial fibrillation after adjustment for age,
Figure 1 Risk of Atrial Fibrillation as a Function of Plasma Leve
High-sensitivity plasma C-reactive protein (CRP) levels were measured in 10,276 in
(Copenhagen City Heart Study) (left panels) and subsequently were followed up fo
tion before study entry were excluded. Findings were retested in 36,600 individual
panels). Multifactorial adjustment was for age, sex, statin use, low-density lipopro
hypertension, hyperthyroidism, and AGT and ACE genotypes (CCHS only). CI  conex, and statin use. The corresponding hazard ratio after
urther adjustment for CRP genotype was 2.22 (95% CI:
.55 to 3.16), and that after multifactorial adjustment was
.77 (95% CI: 1.22 to 2.55). Similar results were seen in the
GPS (Fig. 1).
Heart failure is one of the major risk factors for atrial
brillation, and including heart failure into the multifac-
orial model attenuated the risk of atrial fibrillation
ssociated with the plasma CRP level to 1.47 (95% CI:
.02 to 2.13) for upper versus lower quintile in the
CHS, and similarly in the CGPS (Fig. 2). Adjusting for
lasma fibrinogen level, another marker of inflammation,
ttenuated the corresponding risk of atrial fibrillation to
.63 (95% CI: 1.21 to 2.20) in the CCHS, and similarly
n the CGPS (Fig. 2).
RP genotype and plasma CRP. In accordance with
revious findings (8), the CRP polymorphism rs1205 was
ssociated with lower plasma CRP levels, whereas the
s1130864, rs3091244, and rs3093077 polymorphisms were
CRP in the General Population
als who participated in the 1991 through 1994 examination of The CCHS
15 years with respect to incident atrial fibrillation; individuals with atrial fibrilla-
the cross-sectional CGPS (Copenhagen General Population Study) (right
olesterol, body mass index, smoking, heavy drinking, diabetes mellitus,
e interval.ls of
dividu
r 12 to
s from
tein ch
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Elevated CRP and Atrial Fibrillation August 31, 2010:789–95ssociated with higher CRP levels (Fig. 3). Combining
he genotypes resulted in up to a 63% difference in plasma
RP levels between the lowest and highest levels among
he 9 most common genotype combinations. Contribu-
ion of genotype to variation in plasma CRP levels
stimated as partial r2 values ranged from 1.3% to 1.5%
or the different CRP genotypes or genotype combina-
ions. Covariates (age, lipids, body mass index, alcohol
onsumption, smoking, statin use, hypertension, diabe-
es, heart failure, and AGT and ACE genotype) did not
iffer among the 9 different CRP genotypes (Supplemen-
ary Table) (8).
RP genotype and risk of atrial fibrillation. Hazard
atios for atrial fibrillation as a function of genotype in
he CCHS did not differ consistently from 1.0 for any of
he individual CRP polymorphisms, or for genotype
ombinations (p  0.12 to 0.70 for trend) (Fig. 4). These
ndings were confirmed in the CGPS (p  0.22 to 0.78
or trend). The various risk factors were distributed
qually among the different CRP genotype combinations
Figure 2 Risk of Atrial Fibrillation as a Function of Plasma Leve
General Population, Additionally Adjusted for Heart Fa
Robustness of the association of plasma CRP levels with risk of atrial fibrillation w
levels into the multifactorially adjusted model from Figure 1. This was tested in 10
(left panels), and findings were retested in 36,600 individuals from the cross-sectSupplementary Table) (8). This also was true for each of 1he 4 genotypes separately and for genotype combinations
n each of the studies as previously reported (8).
otential causal effect of CRP on the risk of atrial
brillation. Assuming that elevations in CRP levels have a
ausal effect on risk of atrial fibrillation, genetically elevated
lasma CRP levels should confer a similar increase in
isease risk as that observed for elevated plasma CRP levels
ncountered in the general populations. Based on this
ssumption and to obtain maximal statistical power, we
stimated, using instrumental variable analysis by general-
zed least square regression, that a doubling of plasma CRP
evels resulting from CRP genotype combinations associated
ith a causal odds ratio (OR) of 0.76 (95% CI: 0.62 to 0.93)
n the studies combined, contrasting the observed OR
ssociated with a doubling of plasma CRP levels of 1.12
95% CI: 1.06 to 1.17) in the 2 studies combined (causal vs.
bserved OR, p  0.001). Similar results for unadjusted
nalyses were for plasma CRP 1.36 (95% CI: 1.30 to 1.44)
nd for genetically elevated CRP 0.94 (95% CI: 0.70 to
CRP in the
and Plasma Fibrinogen Levels
ted by separately including adjustment of heart failure and plasma fibrinogen
individuals who participated in the 1991 through 1994 examination of the CCHS
GPS (right panels). Abbreviations as in Figure 1.ls of
ilure
as tes
,276
ional C.27) (causal vs. observed OR, p  0.001) (Fig. 5).
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August 31, 2010:789–95 Elevated CRP and Atrial Fibrillationiscussion
he main findings of this study are that elevated plasma
RP levels are associated robustly with increased risk of
trial fibrillation, but that genetically elevated CRP levels
re not. This suggests that elevated plasma CRP levels per
e do not increase atrial fibrillation risk.
The finding that increased plasma CRP levels associate
ith an increased risk of atrial fibrillation is in accordance
ith a previous prospective study (n  5,806 including 897
vents) (10) and with 3 case-control studies (n  121, n 
02, and n 2,796, respectively) (1,11,12). Also, a previous
tudy from the CCHS showed that plasma fibrinogen,
nother marker of inflammation, associated with risk of
trial fibrillation (13). Importantly, in the present study, we
lso showed that this association is robust, because estimates
nly attenuated slightly when adjusting for CRP genotype,
ultifactorially, and multifactorially including heart failure
nd plasma fibrinogen.
During data analysis, we adjusted estimates of risk asso-
Figure 3 Plasma Levels of CRP as a Function of CRP Genotype
This was tested in 36,600 individuals from the general population, the CGPS. Par
after adjustment for variation in plasma CRP levels resulting from age, sex, and stiated with plasma CRP levels for potential confounders auch as LDL cholesterol, body mass index, smoking, heavy
rinking, diabetes mellitus, hypertension, hyperthyroidism,
nd ACE and AGT genotypes and observed that the risk
stimates largely are not confounded by these factors.
djusting either for heart failure, a well-known risk factor
or atrial fibrillation associated with increased levels of
lasma CRP, or for fibrinogen, another marker of inflam-
ation, somewhat attenuated the risk estimates, although
hey remained significant, also suggesting that plasma CRP
evels robustly predict atrial fibrillation risk.
To study a cause-and-effect relationship such as the one
uggested between plasma CRP levels and risk of atrial
brillation, a Mendelian randomization approach can be
sed to circumvent regression dilution bias, confounding,
nd reverse causation, although, 3 conditions must be
ulfilled (14). First, CRP genotype (instrumental variable)
ust be associated with the exposure variable (plasma
RP). In the present study, CRP genotype combinations
ontributed 1.5% to the total variation in plasma CRP, but
Genotype Combinations
values were determined
se. Abbreviations as in Figure 1.s and
tial r2
atin ussociated with up to a 63% increase in plasma CRP levels.
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Elevated CRP and Atrial Fibrillation August 31, 2010:789–95similar increase in nongenetic plasma CRP is associated
ith a 7% increase in risk of atrial fibrillation (OR: 1.07;
5% CI: 1.04 to 1.10) (Fig. 5); thus, genotype combinations
ssociate with a sufficient increase in plasma CRP to serve
s instruments in a Mendelian randomization study.
econd, CRP genotype must be independent of factors
onfounding the association of plasma CRP levels with risk
f atrial fibrillation, clearly fulfilled in the present studies
Supplementary Table) (8). Finally, CRP genotype must be
ndependent of the outcome, that is, it must not affect risk
f atrial fibrillation by pathways other than plasma CRP,
iven confounding factors (6,14). Having fulfilled these
equirements, comparison of the positive association be-
ween plasma CRP levels and the risk of atrial fibrillation
OR per doubling: 1.12 [95% CI: 1.06 to 1.17]; unadjusted
R: 1.36 [95% CI: 1.30 to 1.44]) with the association
etween genetically elevated CRP levels and risk of atrial
brillation (OR: 0.76 [95% CI: 0.62 to 0.93]; unadjusted
R: 0.94 [95% CI: 0.70 to 1.27]) showed a significant
Figure 4 Risk of Atrial Fibrillation as a Function of CRP Genoty
The hazard and odds ratios were adjusted multifactorially for age, sex, statin use,
tes mellitus, hypertension, hyperthyroidism, and AGT and ACE genotype (CCHS on
examination of the CCHS (left panels), and findings were retested in 36,600 indiv
no events in GG genotype group; other abbreviations as in Figure 1.ontrast, not in favor of a causal relationship between rlevated plasma CRP levels and increased atrial fibrillation
isk. However, because plasma CRP is a marker only of
nflammation, our study does not exclude a potential causal
ssociation between inflammation and atrial fibrillation.
tudy limitations. Potential limitations of this study in-
lude, as always, selection bias and misclassification of
lasma CRP levels, CRP genotype, and atrial fibrillation.
owever, the study populations used were selected using
he national Danish Civil Registration system, drawing 2
andom samples from the Danish adult general popula-
ion without knowledge of plasma CRP levels, genotypes,
nd diagnosis of atrial fibrillation, largely excluding
mportant selection bias. Some misclassification of
lasma markers like CRP is well known because of
egression dilution bias; however, we were able to correct
or this because CRP levels were measured twice in
pproximately 6,300 individuals. Misclassification of ge-
otype is unlikely in the present study, because genotypes
ere controlled by sequencing and because overall call
d Genotype Combinations in the General Population
nsity lipoprotein cholesterol, body mass index, smoking, heavy drinking, diabe-
s was tested in 10,276 individuals who participated in the 1991 through 1994
from the cross-sectional CGPS (right panels). N.A.  not estimated because ofpe an
low-de
ly). Thi
idualsates were more than 99.9% as a result of repeated reruns.
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August 31, 2010:789–95 Elevated CRP and Atrial Fibrillationscertainment and classification of atrial fibrillation is a
otential limitation of the present study because atrial
brillation may have occurred in some individuals with-
ut having been diagnosed, because atrial fibrillation may
ave been coded incorrectly in the national Danish
atient Registry, or because some individuals might not
ave had atrial fibrillation at one of the follow-up
xaminations, that is, if they had paroxystic atrial fibril-
ation. Misclassification of a diagnosis of atrial fibrillation
ould result in an underestimation of the risk estimates,
nd thus more conservative estimates for the association
f plasma CRP levels with risk of atrial fibrillation than
bserved in the present study. Finally, information on
edication, that is, treatment with statin and antihyper-
ensive medication, is self-reported and may be inaccu-
ate. Such an inaccuracy tends to make association of
lasma CRP levels with risk of atrial fibrillation more
onservative, but would not influence the association of
RP genotype with risk of atrial fibrillation.
onclusions
levated plasma CRP was robustly associated with in-
reased risk of atrial fibrillation, although genetically
levated CRP levels were not. This suggests that elevated
lasma CRP per se does not increase atrial fibrillation
Figure 5 Studies Summary of the Causal Effect of CRP on
Risk of Atrial Fibrillation in the General Population
The causal effect of CRP on risk of atrial fibrillation was estimated by the asso-
ciation between genetically elevated CRP levels and risk of atrial fibrillation,
using instrumental variable analysis by generalized least square regression
(solid line). This risk is compared with the observed risk associated with
plasma CRP in the general population (dashed line). For comparison, risk esti-
mates for a doubling (100% increase) in CRP levels are given. Estimates are
based on the combined studies with 10,276 individuals from the CCHS and
36,600 individuals from the CGPS. OR  odds ratio; other abbreviations as in
Figure 1.isk. pcknowledgments
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